ProQR Therapeutics NV (MEX:PRQRN) Change In Receivables: MXN0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PRQRN ProQR Therapeutics NV MEX:PRQRN
50 GF Score
Price MXN36.00
GF Value MXN37.10
! 2 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Change In Receivables?

ProQR Therapeutics NV MEX:PRQRN 50 Change In Receivables is MXN0.0 Mil as of Jun. 2026. GuruFocus rates MEX:PRQRN with a GF Score™ of 50/100 and a GF Value™ of MXN37.10. The stock has 2 warning signs investors should review.

ProQR Therapeutics NV's change in receivables for the quarter that ended in Jun. 2026 was MXN0.0 Mil. It means ProQR Therapeutics NV's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

ProQR Therapeutics NV's change in receivables for the fiscal year that ended in Dec. 2025 was MXN0.0 Mil. It means ProQR Therapeutics NV's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

ProQR Therapeutics NV's Accounts Receivable for the quarter that ended in Jun. 2026 was MXN78.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. ProQR Therapeutics NV's Days Sales Outstanding for the three months ended in Jun. 2026 was 40.71.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ProQR Therapeutics NV's liquidation value for the three months ended in Jun. 2026 was MXN1,326.4 Mil.

ProQR Therapeutics NV  (MEX:PRQRN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ProQR Therapeutics NV's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=78.561/176.078*91
=40.71

2. In Ben Graham's calculation of liquidation value, ProQR Therapeutics NV's accounts receivable are only considered to be worth 75% of book value:

ProQR Therapeutics NV's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=2354.509-1087.065+0.75 * 78.561+0.5 * 0
=1,326.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Change In Receivables Related Terms

ProQR Therapeutics NV Change In Receivables Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Change In Receivables Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ProQR Therapeutics NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:PRQRN
50GF Score
ProQR Therapeutics NV MEX:PRQRN
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProQR Therapeutics NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of MXN0.0 Mil mean?
ProQR Therapeutics NV (MEX:PRQRN) has a Change In Receivables of MXN0.0 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's Change In Receivables too high?
ProQR Therapeutics NV's current Change In Receivables is MXN0.0 Mil. Overall, ProQR Therapeutics NV has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Change In Receivables compare to NWBO and IMRX?
ProQR Therapeutics NV's Change In Receivables of MXN0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Change In Receivables is MXN0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current Change In Receivables of MXN0.0 Mil. The stock's GF Value™ is MXN37.10, compared to a current price of MXN36.00 — trading 3% below its estimated fair value. The current Change In Receivables is MXN0.0 Mil. ProQR Therapeutics NV's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Change In Receivables is MXN0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 3% below its estimated GF Value™ of MXN37.10.

Key valuation signals for MEX:PRQRN:

  • Change In Receivables: MXN0.0 Mil
  • GF Value™: MXN37.10 vs. price of MXN36.00 (3% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score

Get the complete analysis for MEX:PRQRN

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00
Price
MXN37.10
GF Value